Home page  |  Help  |  Clear
English  |  French
 Search  |  Categories  |  Titles A-Z  |  Countries  |  Compare countries  |  Index  
Full TOC
Expand Document
Expand Chapter
Preferences

close this bookStandard Treatment Guidelines (STG) and The National Essential Drug List for Tanzania (NEDLIT) (WHO; 1997; 210 pages)
View the documentFOREWORD
View the documentACKNOWLEDGMENTS
View the documentINTRODUCTION
close this folderStandard Treatment Guidelines (STG)
Open this folder and view contents1. GASTROINTESTINAL CONDITIONS
Open this folder and view contents2. RESPIRATORY DISEASES
Open this folder and view contents3. OBSTETRIC AND GYNAECOLOGICAL CONDITIONS AND CONTRACEPTION
Open this folder and view contents4. CARDIOVASCULAR DISEASES
Open this folder and view contents5. MALARIA
Open this folder and view contents6. SKIN DISEASES
Open this folder and view contents7. SEXUALLY TRANSMITTED INFECTIONS / DISEASES (STD)
Open this folder and view contents8. DENTAL AND ORAL CONDITIONS
Open this folder and view contents9. GENITO-URINARY DISEASES: KIDNEY CONDITIONS
Open this folder and view contents10. EAR, NOSE AND THROAT CONDITIONS
Open this folder and view contents11. EYE CONDITIONS
Open this folder and view contents12. TUBERCULOSIS AND LEPROSY
Open this folder and view contents13. MUSCULOSKELETAL CONDITIONS AND JOINT DISEASES
Open this folder and view contents14. METABOLIC AND ENDOCRINE SYSTEM CONDITIONS
Open this folder and view contents15. CENTRAL NERVOUS SYSTEM DISEASE CONDITIONS
Open this folder and view contents16. OTHER DISEASE CONDITIONS
Open this folder and view contents17. VIRAL INFECTIONS
Open this folder and view contents18. ALLERGIC REACTIONS
close this folder19. NUTRITIONAL AND HAEMATOLOGIC CONDITIONS
close this folderHAEMATOLOGICAL DISEASE CONDITIONS
View the document19.1 Anaemia
View the document19.2 Sickle Cell Anaemia
View the document19.3 Q6PD deficiency
Open this folder and view contents19.4 Bleeding Disorders
View the document19.5 Von Willebrand Disease (VWD)
View the document19.6 Acquired Bleeding Disorders/Platelet Disorders
View the document19.7 Haemorrhagic Disease of the Newborn
View the document19.8 Anticoagulation
Open this folder and view contentsNUTRITIONAL DISEASE CONDITIONS
Open this folder and view contents20. MALIGNANT DISEASE CONDITIONS
Open this folder and view contents21. INJURIES AND TRAUMA
View the document22. FOREIGN BODIES
View the document23. PAIN
View the document24. POISONING
View the document25. NORMAL LABORATORY VALUES
Open this folder and view contentsNATIONAL ESSENTIAL DRUG LIST
View the documentABBREVIATIONS AND SYMBOLS
 
19.8 Anticoagulation

Duration of treatment.

• Deep vein thrombosis (DVT): 6 - 8 weeks

Except in pregnancy, or if there is another reason for prolonged treatment.

• Pulmonary embolism (PE): 3 months

• Atrial fibrillation: life long treatment.

• Heart valve prostheses: life long treatment.


Heparin Treatment

Prophylaxis against DVT

following surgery and immobility e.g cardiac failure:

Heparin (SC) 5000 units every 8 hours until ambulant.


Treatment of DVT/PE

Heparin (IV) 10000 units every 6 hours.

Monitor APTT - aim for 2-3 times control.
Continue until warfarin is effective, usually 3-5 days.


If facilities for monitoring APTT and INR are not available, DVT, may be treated with:

Heparin (SC) 10000 units twice daily for 3 - 4 weeks.


DVT in pregnancy

Continue throughout pregnancy, aiming for APTT 2-3 times normal:

Heparin (SC) 10000 units twice daily;

OR


Warfarin after first trimester (12 weeks) keeping INR in the range 2-3. At 32-34 weeks stop Warfarin and change to Heparin as above.


CAUTION Warfarin may harm the foetus and should not be used under 12 weeks. Monitor closely whichever method is used. Specialist supervision is recommended.

Heparin Overdosage

If bleeding occurs, stop heparin and give:

Protamine sulphate (slow IV) 1 mg neutralises 100 units of Heparin. Maximum dose 50 mg (in excess protamine is also an anticoagulant).


Oral Anticoagulation

Warfarin (O) loading dose 10 mg once daily for 2 days. Check INR on 3rd day and dose accordingly. The drug should be taken at the same time each day.


Therapeutic Range for Warfarin use

DVT/PE: INR 2-3, heart valve prosthesis: INR 3-4.5.

There is great individual variation in dose (average daily dose 3-9 mg). Monitor INR regularly, initially daily/ alternate days then increase interval gradually to a maximum of 8 weeks. Reduce loading dose in elderly and in patients with renal/ hepatic impairment.

Drugs Interacting with Warfarin

CAUTION Drug interactions are common and can be dangerous

Below are a few examples:

Warfarin Inhibition

Warfarin Potentiation

Barbiturates

Alcohol

Oral contraceptives

Chloramphenicol

Griseofulvin

Cimetidine

Rifampicin

Erythromycin

Carbamazepine

Co-trimoxazole

Vitamin K

Acetylsalicylic acid

Warfarin Overdosage:

If INR 4.5-7 without haemorrhage - withhold Warfarin for 1-2 days then review.

If INR > 7 without haemorrhage - withhold Warfarin and check INR daily.

Consider giving:

Vitamin K (slow IV) 0.5-1 mg injection (not IM).

If INR > 4.5 with haemorrhage, give:

Fresh frozen plasma (FFP) 2-4 bags, then check INR and repeat infusion if bleeding continues.

Plus


Vitamin K (slow IV) 0.5 - 1 mg (higher doses Vitamin K will prevent adequate anticoagulation for up to 2 weeks).


Streptokinase Treatment

Life Threatening Pulmonary Embolism / Arterial Embolism

Streptokinase (IV) loading dose of 250000 units over 30 minutes, then 100000 units every hour for 24-72 hours

CAUTION allergic reactions may occur - before infusion give: hydrocortisone (IV) 100 mg.

to previous sectionto next section

Please provide your feedback
Abbreviations
English  |  French